## Giuseppe Lucarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1344417/publications.pdf

Version: 2024-02-01

66343 133252 4,879 159 42 59 citations h-index g-index papers 161 161 161 7444 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	1.3	4
2	3D Clampless Robot-Assisted Partial Nephrectomy for Endophytic Hilar Renal Mass. Urology Video Journal, 2022, 13, 100120.	0.2	1
3	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
4	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	2.6	14
5	Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 3826.	4.1	31
6	Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical Genitourinary Cancer, 2022, 20, e166-e172.	1.9	26
7	Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice. European Urology Open Science, 2022, 39, 1-6.	0.4	11
8	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. International Journal of Molecular Sciences, 2022, 23, 4173.	4.1	40
9	Xi Nerve-sparing Robotic Radical Perineal Prostatectomy: European Single-center Technique and Outcomes. European Urology Open Science, 2022, 41, 55-62.	0.4	2
10	Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. Biomedicines, 2022, 10, 1287.	3.2	10
11	Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Cancers, 2022, 14, 2545.	3.7	37
12	Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 490.e13-490.e20.	1.6	19
13	Radiomics in prostate cancer: an up-to-date review. Therapeutic Advances in Urology, 2022, 14, 175628722211090.	2.0	62
14	Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. European Urology, 2021, 80, 95-103.	1.9	29
15	Safety and Feasibility of Outpatient Surgery in Benign Prostatic Hyperplasia: a Systematic Review and Meta-Analysis. Journal of Endourology, 2021, 35, 395-408.	2.1	20
16	DelCFHR3â€1 influences graft survival in transplant patients with IgA nephropathy via complementâ€mediated cellular senescence. American Journal of Transplantation, 2021, 21, 838-845.	4.7	8
17	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Critical Reviews in Oncology/Hematology, 2021, 157, 103198.	4.4	35
18	Narrative review of Mediterranean diet in Cilento: longevity and potential prevention for prostate cancer. Therapeutic Advances in Urology, 2021, 13, 175628722110264.	2.0	4

#	Article	IF	Citations
19	Robotic radical perineal prostatectomy: tradition and evolution in the robotic era. Current Opinion in Urology, 2021, 31, 11-17.	1.8	10
20	Characterization of Cytotoxic T (CTL) by Tissue. Methods in Molecular Biology, 2021, 2325, 107-124.	0.9	0
21	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. Diagnostics, 2021, 11, 355.	2.6	12
22	Artificial Intelligence and Machine Learning in Prostate Cancer Patient Managementâ€"Current Trends and Future Perspectives. Diagnostics, 2021, 11, 354.	2.6	64
23	Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 237.	2.5	58
24	Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury. Aging, 2021, 13, 10920-10933.	3.1	9
25	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers, 2021, 13, 2047.	3.7	45
26	Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: an evidence-based analysis of comparative outcomes. World Journal of Urology, 2021, 39, 3721-3732.	2.2	37
27	Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation. Transplantology, 2021, 2, 191-207.	0.6	4
28	"Non-Parasitic―and "Non-latrogenic―Chyluria: Its Diagnosis and Treatment. Surgical Case Reports, 2021, , 1-3.	0.0	0
29	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in Oncology, 2021, 11, 651745.	2.8	11
30	Fascin-1 and its role as a serological marker in prostate cancer: a prospective case–control study. Future Science OA, 2021, 7, FSO745.	1.9	7
31	Modified Technique for Wirsung-Pancreatogastric Anastomosis after Pancreatoduodenectomy: A Single Center Experience and Systematic Review of the Literature. Journal of Clinical Medicine, 2021, 10, 3064.	2.4	4
32	A risk-group classification model in patients with Abladder cancer Aunder neoad juvant cisplatin-based combination chemotherapy. Future Oncology, 2021, 17, 3987-3994.	2.4	3
33	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Science OA, 2021, 7, FSO709.	1.9	40
34	The Association between Mortality and Male Infertility: Systematic Review and Meta-analysis. Urology, 2021, 154, 148-157.	1.0	21
35	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	2.5	23
36	Prostate Cancer Radiogenomicsâ€"From Imaging to Molecular Characterization. International Journal of Molecular Sciences, 2021, 22, 9971.	4.1	55

#	Article	IF	CITATIONS
37	Mechanical and Ablative Minimally Invasive Techniques for Male LUTS due to Benign Prostatic Obstruction: A Systematic Review according to BPH-6 Evaluation. Urologia Internationalis, 2021, 105, 858-868.	1.3	9
38	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	1.4	20
39	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	3.7	21
40	64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?. Minerva Urology and Nephrology, 2021, 73, 668-671.	2.5	2
41	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva Urology and Nephrology, 2021, , .	2.5	3
42	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology, 2020, 38, 143-150.	2.2	49
43	Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs. Medicine (United) Tj ETQq $1\ 1\ 0.78^4$	1 <b>3.</b> 1⁄4 rgBT	<i>h</i> Overlock
44	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology, 2020, 39, 1861-1867.	2.2	14
45	36-kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in Clear Cell Renal Cell Carcinoma Cells. American Journal of Pathology, 2020, 190, 2317-2326.	3.8	53
46	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy, 2020, 21, 2199-2204.	1.8	3
47	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. Frontiers in Surgery, 2020, 7, 563006.	1.4	17
48	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. Metabolites, 2020, 10, 509.	2.9	51
49	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. Urologia Internationalis, 2020, 104, 510-522.	1.3	17
50	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	1.6	42
51	Management of severe complications following penile surgery for erectile dysfunction and Peyronie disease. Medicine (United States), 2020, 99, e18690.	1.0	1
52	Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences, 2020, 21, 1184.	4.1	45
53	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 151, 102992.	4.4	28
54	Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity. Aging, 2020, 12, 4337-4347.	3.1	9

#	Article	IF	CITATIONS
55	PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging, 2020, 12, 7585-7602.	3.1	78
56	PD38-10â€∱ADDING SYSTEMATIC BIOPSY (SBX) TO MAGNETIC RESONANCE ULTRASOUND FUSION TARGETED BIOPSY (TBX) OF THE PROSTATE IN MEN WITH PREVIOUS NEGATIVE BIOPSY OR ENROLLED IN ACTIVE SURVEILLANCE PROGRAMS: A PROSPECTIVE SINGLE CENTER, RANDOMIZED, ANALYSIS. Journal of Urology, 2020, 203, .	0.4	O
57	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	2.2	77
58	Renal progenitor cells revert LPSâ€induced endothelialâ€toâ€mesenchymal transition by secreting CXCL6, SAA4, and BPIFA2 antiseptic peptides. FASEB Journal, 2019, 33, 10753-10766.	0.5	35
59	Recurrent urinary tract infections in kidney transplant recipients during the first-year influence long-term graft function: a single-center retrospective cohort study. Journal of Nephrology, 2019, 32, 661-668.	2.0	25
60	Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Review of Molecular Diagnostics, 2019, 19, 397-407.	3.1	133
61	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Review of Molecular Diagnostics, 2019, 19, 377-387.	3.1	43
62	Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 355.e11-355.e19.	1.6	67
63	Penile prosthesis implant for primary erectile dysfunction in patient with Klippel-Trenaunay syndrome complicated by consumptive coagulopathy. Medicine (United States), 2019, 98, e16741.	1.0	3
64	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. World Journal of Urology, 2019, 37, 1049-1059.	2.2	5
65	High-throughput detection of low abundance sialylated glycoproteins in human serum by TiO2 enrichment and targeted LC-MS/MS analysis: application to a prostate cancer sample set. Analytical and Bioanalytical Chemistry, 2019, 411, 755-763.	3.7	18
66	Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/ $\hat{l}^2$ catenin signaling after ischemia/reperfusion injury. Aging, 2019, 11, 4382-4406.	3.1	66
67	Integrative diagnosis, biological observations, and histopathology of the fig cyst nematode Heterodera fici Kirjanova (1954) associated with Ficus carica L. in southern Italy. ZooKeys, 2019, 824, 1-19.	1.1	3
68	Clinical management of a unique case of PNET of the uterus during pregnancy, and review of the literature. Medicine (United States), 2018, 97, e9505.	1.0	5
69	Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. Medicine (United States), 2018, 97, e0522.	1.0	10
70	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus, 2018, 4, 874-879.	3.1	30
71	Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging, 2018, 10, 3957-3985.	3.1	133
72	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer. European Urology Oncology, 2018, 1, 403-410.	5.4	66

#	Article	IF	Citations
73	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. Journal of Cancer, 2018, 9, 4250-4254.	2.5	26
74	FP728GRAFT FUNCTION IN KIDNEY TRANSPLANT PATIENTS WITH IGA NEPHROPATHY IS INFLUENCED BY VARIANTS IN COMPLEMENT FACTOR H. Nephrology Dialysis Transplantation, 2018, 33, i291-i291.	0.7	0
75	FP693RENAL ACUTE AND CHRONIC ANTIBODY-MEDIATED REJECTION (AMR) ACCELERATE THE TUBULAR SENESCENCE INCREASING THE EXPRESSION OF CELL CYCLE NEGATIVE REGULATORS. Nephrology Dialysis Transplantation, 2018, 33, i279-i280.	0.7	0
76	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	1.3	22
77	Complement Activation During Ischemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling. Frontiers in Immunology, 2018, 9, 1002.	4.8	47
78	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	1.9	55
79	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 2018, 9, 19861-19873.	1.8	37
80	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clinical Genitourinary Cancer, 2018, 16, 385-391.	1.9	33
81	Aligned Nanofiber Topographies Enhance the Differentiation of Adult Renal Stem Cells into Glomerular Podocytes. Advanced Engineering Materials, 2018, 20, 1800003.	3.5	5
82	The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma. Translational Cancer Research, 2018, 7, S766-S769.	1.0	8
83	Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. Oncology, 2017, 92, 125-134.	1.9	14
84	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e661-e666.	1.9	47
85	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Medicine (United States), 2017, 96, e6817.	1.0	4
86	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e15-461.e27.	1.6	75
87	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Translational Research, 2017, 184, 108-117.	5.0	56
88	Outcomes of robot-assisted simple enucleation of renal masses. Medicine (United States), 2017, 96, e6771.	1.0	4
89	The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncology, 2017, 13, 285-293.	2.4	55
90	Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS). International Journal of Molecular Sciences, 2017, 18, 1146.	4.1	13

#	Article	IF	CITATIONS
91	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget, 2017, 8, 18424-18434.	1.8	52
92	Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget, 2017, 8, 40412-40424.	1.8	50
93	The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget, 2017, 8, 113502-113515.	1.8	95
94	Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (Basel, Switzerland), 2016, 4, 7.	2.5	62
95	Experience of percutaneous access under ultrasound guidance in renal transplant patients with allograft lithiasis. Archivio Italiano Di Urologia Andrologia, 2016, 88, 337.	0.8	4
96	Multi-omics approach reveals the secrets of metabolism of clear cellâ€"renal cell carcinoma. Translational Andrology and Urology, 2016, 5, 801-803.	1.4	14
97	Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy. Medicine (United States), 2016, 95, e2551.	1.0	23
98	Complement Modulation of Anti-Aging Factor Klotho in Ischemia/Reperfusion Injury and Delayed Graft Function. American Journal of Transplantation, 2016, 16, 325-333.	4.7	83
99	Prognostic Factors for Anastomotic Urinary Leakage Following Retropubic Radical Prostatectomy and Correlation With Voiding Outcomes. Medicine (United States), 2016, 95, e3475.	1.0	9
100	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United) Tj ETQq0 0 C	rgBT /Ov	erlock 10 Tf 5
101	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opinion on Biological Therapy, 2016, 16, 1387-1401.	3.1	22
102	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. Journal of Translational Medicine, 2016, 14, 84.	4.4	34
103	A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma. Medicine (United) Tj ETQq1 1	0.784314 1.0	rgBT  Overlo
104	Biomarkers in localized prostate cancer. Future Oncology, 2016, 12, 399-411.	2.4	39
105	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	1.0	43
106	The Role of Renal Surgery in the Era of Targeted Therapy: The Urologist's Perspective. Urologia, 2015, 82, 137-138.	0.7	27
107	Third-Line Chemotherapy for Metastatic Urothelial Cancer. Medicine (United States), 2015, 94, e2297.	1.0	16
108	Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 2015, 6, 13371-13386.	1.8	138

#	Article	IF	Citations
109	Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction. Medicine (United States), 2015, 94, e1556.	1.0	34
110	Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. Medicine (United States), 2015, 94, e1917.	1.0	48
111	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell–Renal Cell Carcinoma. Medicine (United States), 2015, 94, e2117.	1.0	45
112	Cystocele Repair by Autologous Rectus Fascia Graft: the Pubovaginal Cystocele Sling. Journal of Urology, 2015, 194, 721-727.	0.4	22
113	Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2015, 30, 1403-1411.	0.7	147
114	Isolation and Characterization of Cancer Stem Cells in Renal Cell Carcinoma. Urologia, 2015, 82, 46-53.	0.7	14
115	Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1211-1224.	3.1	57
116	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy, 2015, 11, 2102-2113.	9.1	27
117	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncology, 2015, 11, 3091-3098.	2.4	17
118	Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World Journal of Urology, 2015, 33, 1-7.	2.2	51
119	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. PLoS ONE, 2015, 10, e0139696.	2.5	39
120	Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Anticancer Research, 2015, 35, 1017-23.	1.1	35
121	Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer. Anticancer Research, 2015, 35, 2175-82.	1.1	13
122	Emerging Biomarkers in Renal Damage. BioMed Research International, 2014, 2014, 1-2.	1.9	1
123	Capillary hemangioma of the scrotum mimicking an epididymal tumor: Case report. Archivio Italiano Di Urologia Andrologia, 2014, 86, 395.	0.8	6
124	Emerging Urinary Markers of Renal Injury in Obstructive Nephropathy. BioMed Research International, 2014, 2014, 1-7.	1.9	58
125	Long-Term Results of Combined Tunica Albuginea Plication and Penile Prosthesis Implantation for Severe Penile Curvature and Erectile Dysfunction. Case Reports in Urology, 2014, 2014, 1-3.	0.3	1
126	Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma. Disease Markers, 2014, 2014, 1-9.	1.3	47

#	Article	IF	CITATIONS
127	Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrology Dialysis Transplantation, 2014, 29, 799-808.	0.7	98
128	Editorial Comment from Dr Lucarelli and Dr Ditonno to Impact of graft nephrectomy on outcomes of second kidney transplantation. International Journal of Urology, 2014, 21, 802-803.	1.0	1
129	CTR2 Identifies a Population of Cancer Cells with Stem Cell-like Features in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1831-1841.	0.4	35
130	Pre-existing Type 2 Diabetes Mellitus Is an Independent Risk Factor for Mortality and Progression in Patients With Renal Cell Carcinoma. Medicine (United States), 2014, 93, e183.	1.0	45
131	Impact of donor–recipient gender on kidney graft and patient survival: short- and long-term outcomes. World Journal of Urology, 2014, 32, 709-714.	2.2	9
132	Hem-O-Lok clip: a neglected cause of severe bladder neck contracture and consequent urinary incontinence after robot-assisted laparoscopic radical prostatectomy. BMC Urology, 2014, 14, 21.	1.4	25
133	A Single-Center Cohort Study to Define the Role of Pretransplant Biopsy Score in the Long-term Outcome of Kidney Transplantation. Transplantation, 2014, 97, 934-939.	1.0	19
134	Long-Term Results of Radical Surgery and Adjuvant Radiotherapy in a Case of Primary Malignant Fibrous Histiocytoma of the Kidney. The Open Urology & Nephrology Journal, 2014, 7, 1-3.	0.2	1
135	Impact of transplant nephrectomy on retransplantation: a single-center retrospective study. World Journal of Urology, 2013, 31, 959-963.	2.2	24
136	Delayed Relief of Ureteral Obstruction is Implicated in the Long-Term Development of Renal Damage and Arterial Hypertension in Patients with Unilateral Ureteral Injury. Journal of Urology, 2013, 189, 960-965.	0.4	61
137	Middle and Long-term Outcomes of Dual Kidney Transplant: A Multicenter Experience. Transplantation Proceedings, 2013, 45, 1237-1241.	0.6	15
138	Spondin-2, a Secreted Extracellular Matrix Protein, is a Novel Diagnostic Biomarker for Prostate Cancer. Journal of Urology, 2013, 190, 2271-2277.	0.4	67
139	The protonophore CCCP interferes with lysosomal degradation of autophagic cargo in yeast and mammalian cells. Autophagy, 2013, 9, 1862-1875.	9.1	78
140	Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 899-907.	2.4	35
141	Allograft Nephrectomy: What Is the Best Surgical Technique?. Transplantation Proceedings, 2012, 44, 1922-1925.	0.6	11
142	Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate, 2012, 72, 1611-1621.	2.3	83
143	Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. International Journal of Oncology, 2011, 39, 1233-42.	3.3	11
144	Obesity in Kidney Transplantation Affects Renal Function But Not Graft and Patient Survival. Transplantation Proceedings, 2011, 43, 367-372.	0.6	42

#	Article	IF	Citations
145	High energy microwave thermotherapy for symptomatic benign prostatic enlargment: predictive parameters of long term outcome. Archivio Italiano Di Urologia Andrologia, 2011, 83, 83-7.	0.8	2
146	Patient and Partner Satisfaction after AMS Inflatable Penile Prosthesis Implant. Journal of Sexual Medicine, 2010, 7, 304-309.	0.6	84
147	Retroperitoneal less donor nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 602-608.	1.5	3
148	Transperitoneal Deviceless Hand-Assisted Laparoscopic Living Donor Nephrectomy: An Alternative Technique for Kidney Recovery. Journal of Endourology, 2010, 24, 1617-1623.	2.1	5
149	Extended Criteria Donor Kidney Transplantation: Comparative Outcome Analysis Between Single versus Double Kidney Transplantation at 5 Years. Transplantation Proceedings, 2010, 42, 1104-1107.	0.6	36
150	Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. American Journal of Pathology, 2010, 176, 1648-1659.	3.8	136
151	Penile prosthesis implant: when, what and how. Journal of Men's Health, 2009, 6, 299-306.	0.3	1
152	Androgen deprivation therapy regulation of $\hat{I}^21\text{C}$ integrin expression in prostate cancer. Oncology Reports, 2009, , .	2.6	2
153	Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer. Oncology Reports, 2009, 22, 327-35.	2.6	6
154	Unusual solitary metastasis of the ciliary body in renal cell carcinoma. International Journal of Urology, 2008, 15, 363-365.	1.0	12
155	Incidentally Discovered Yellowish Lesions in a Renal Graft From a Deceased Donor. Transplantation Proceedings, 2008, 40, 2062-2064.	0.6	7
156	"Deviceless―Hand-Assisted Laparoscopic Donor Nephrectomy. Transplantation Proceedings, 2008, 40, 1829-1830.	0.6	4
157	Penile Prosthesis: What Should We Do about Complications?. Advances in Urology, 2008, 2008, 1-5.	1.3	28
158	Testicular granulosa cell tumor of adult type: A new case and a review of the literature. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 322-325.	1.6	23
159	Incidental Prostatic Cancer: Repeat TURP or Biopsy?. Urologia Internationalis, 2004, 73, 193-197.	1.3	12